Acuitas Therapeutics is a pioneer in developing lipid nanoparticals, and already has seen two approved products: ONPATTRO and the Pfizer/BioNTech mRNA vaccine

Co-Founder & CEO Thomas Madden describes the science and history behind LNPs, and discusses what is currently in development, including trying to use them to deliver therapies outside of the liver.